UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2104-19
Program Prior Authorization/Medical Necessity
Medication Taltz (ixekizumab)*
* Taltz is excluded from coverage for the majority of our benefits
P&T Approval Date 8/2016, 5/2017, 2/2018, 2/2019, 9/2019, 5/2020, 7/2020, 11/2020,
6/2021, 12/2021, 3/2022, 6/2022, 11/2022, 1/2023, 4/2023, 7/2023,
10/2024, 4/2025
Effective Date 6/1/2025
1. Background:
Taltz (ixekizumab) is a humanized interleukin-17A antagonist indicated for the treatment of
moderate to severe plaque psoriasis in patients aged 6 years or older who are candidates for
systemic therapy or phototherapy. It is also indicated for the treatment of adult patients with
active psoriatic arthritis, active non-radiographic axial spondyloarthritis with objective signs of
inflammation, or active ankylosing spondylitis.1
2. Coverage Criteriaa:
A. Plaque Psoriasis (PsO)
a. Taltz will be approved based on all of the following criteria:
(1) Submission of medical records (e.g., chart notes, laboratory values) documenting
all of the following:
(a) One of the following:
i. All of the following:
a. Diagnosis of chronic moderate to severe plaque psoriasis
-AND-
b. One of the following:
1. All of the following:
a.) Greater than or equal to 3 % body surface area involvement,
palmoplantar, facial, genital involvement, or severe scalp
psoriasis
-AND-
© 2025 UnitedHealthcare Services Inc.
1
b.) History of failure to one of the following topical therapies,
unless contraindicated or clinically significant adverse
effects are experienced (document drug, date, and duration
of trial):
• Corticosteroids (e.g., betamethasone, clobetasol,
desonide)
• Vitamin D analogs (e.g., calcitriol, calcipotriene)
• Tazarotene
• Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
• Anthralin
• Coal tar
-AND-
c.) History of failure to a 3 month trial of methotrexate at
maximally indicated dose, unless contraindicated or
clinically significant adverse effects are experienced
(document date and duration of trial)b
-OR-
2. Patient has been previously treated with a targeted
immunomodulator FDA-approved for the treatment of plaque
psoriasis as documented by claims history or submission of
medical records (Document drug, date, and duration of therapy)
[e.g., Cimzia (certolizumab), adalimumab, Otezla (apremilast),
Skyrizi (risankizumab-rzaa), ustekinumab, Tremfya
(guselkumab), Enbrel (etanercept)].
-AND-
c. History of failure, contraindication, or intolerance to three of the
following preferred products (document drug, date, and duration of
trial):
• One of the preferred adalimumab productsc
• Cimzia (certolizumab)
• Cosentyx (secukinumab)
• Enbrel (etanercept)
• Skyrizi (risankizumab)
• Sotyktu (deucravacitinib)
• One of the preferred ustekinumab productsc
• Tremfya (guselkumab)
-OR-
ii. All of the following:
© 2025 UnitedHealthcare Services Inc.
2
a. Diagnosis of chronic moderate to severe plaque psoriasis
-AND-
b. Patient is less than 18 years of age
-AND-
c. History of failure, contraindication, or intolerance to Cosentyx
(secukinumab), Enbrel (etanercept), or one of the preferred
ustekinumab productsc(document date and duration of trial)
-AND-
(b) Patient is not receiving Taltz in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Simponi (golimumab), Orencia (abatacept), adalimumab, ustekinumab,
Skyrizi (risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab),
Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant
(baricitinib), Rinvoq (upadacitinib), Sotyktu (deucravacitinib), Otezla
(apremilast)]
-AND-
(c) Prescribed by or in consultation with a dermatologist
Authorization will be issued for 12 months.
B. Psoriatic Arthritis (PsA)
a. Taltz will be approved based on the following criteria:
(1) Submission of medical records (e.g., chart notes, laboratory values) documenting
all of the following:
(a) Diagnosis of active psoriatic arthritis
-AND-
(b) One of the following:
i. History of failure to a 3 month trial of methotrexate at maximally
indicated dose, unless contraindicated or clinically significant adverse
effects are experienced (document date and duration of trial)b
-OR-
ii. Patient has been previously treated with a targeted immunomodulator
FDA-approved for the treatment of psoriatic arthritis as documented by
claims history or submission of medical records (Document drug, date,
© 2025 UnitedHealthcare Services Inc.
3
and duration of therapy) [e.g., Cimzia (certolizumab), Cosentyx
(secukinumab), adalimumab, Simponi (golimumab), ustekinumab,
Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Otezla
(apremilast), Skyrizi (risankizumab), Rinvoq (upadacitinib), Enbrel
(etanercept)]
-AND-
(c) History of failure, contraindication, or intolerance to three of the following
preferred products (document drug, date, and duration of trial):
i. One of the preferred adalimumab productsc
ii. Cimzia (certolizumab)
iii. Cosentyx (secukinumab)
iv. Enbrel (etanercept)
v. Simponi (golimumab)
vi. Skyrizi (risankizumab)
vii. One of the preferred ustekinumab productsc
viii. Tremfya (guselkumab)
-AND-
(d) History of failure, contraindication, or intolerance to one of the following
(document drug, date, and duration of trial):
i. Orencia (abatacept)
ii. Xeljanz/Xeljanz XR (tofacitinib)
iii. Rinvoq (upadacitinib)
-AND-
(e) Patient is not receiving Taltz in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi
(golimumab), Orencia (abatacept), adalimumab, ustekinumab, Skyrizi
(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Xeljanz
(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla
(apremilast)]
-AND-
(f) Prescribed by or in consultation with one of the following:
i. Rheumatologist
ii. Dermatologist
Authorization will be issued for 12 months.
C. Ankylosing Spondylitis (AS)
a. Taltz will be approved based on the following criteria:
© 2025 UnitedHealthcare Services Inc.
4
(1) Submission of medical records (e.g., chart notes, laboratory values) documenting
all of the following:
(a) Diagnosis of active ankylosing spondylitis
-AND-
(b) One of the following:
i. History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally
indicated doses, each used for at least 4 weeks, unless contraindicated or
clinically significant adverse effects are experienced (document drug, date,
and duration of trials)
-OR-
ii. Patient has been previously treated with a targeted immunomodulator
FDA-approved for the treatment of ankylosing spondylitis as documented
by claims history or submission of medical records (Document drug, date,
and duration of therapy) [e.g., adalimumab, Simponi (golimumab), Rinvoq
(upadacitinib), Xeljanz/Xeljanz XR (tofacitinib), Enbrel (etanercept)].
-AND-
(c) History of failure, contraindication, or intolerance to three of the following
preferred products (document drug, date, and duration of trial):
i. One of the preferred adalimumab productsc
ii. Cimzia (certolizumab)
iii. Cosentyx (secukinumab)
iv. Enbrel (etanercept)
v. Simponi (golimumab)
-AND-
(d) History of failure, contraindication, or intolerance to one of the following
(document drug, date, and duration of trial):
i. Xeljanz/Xeljanz XR (tofacitinib)
ii. Rinvoq (upadacitinib)
-AND-
(e) Patient is not receiving Taltz in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Cosentyx (secukinumab), Simponi (golimumab), Orencia (abatacept),
adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib)]
© 2025 UnitedHealthcare Services Inc.
5
-AND-
(f) Prescribed by or in consultation with a rheumatologist
Authorization will be issued for 12 months.
D. Non-radiographic Axial Spondyloarthritis
a. Taltz will be approved based on the following criteria:
(1) Submission of medical records (e.g., chart notes, laboratory values) documenting
all of the following:
(a) Diagnosis of active non-radiographic axial spondyloarthritis
-AND-
(b) One of the following:
i. History of failure to two NSAIDs (e.g., ibuprofen, naproxen) at maximally
indicated doses, each used for at least 4 weeks, unless contraindicated or
clinically significant adverse effects are experienced (document drug, date,
and duration of trials)
-OR-
ii. Patient has been previously treated with a targeted immunomodulator
FDA-approved for the treatment of non-radiographic axial
spondyloarthritis as documented by claims history or submission of
medical records (Document drug, date, and duration of therapy) [e.g.
Cimzia (certolizumab), Cosentyx (secukinumab), Rinvoq (upadacitinib)].
-AND-
(c) History of failure, contraindication, or intolerance to two of the following
preferred products (document drug, date, and duration of trial):
i. Cimzia (certolizumab)
ii. Cosentyx (secukinumab)
iii. Rinvoq (upadacitinib)
-AND-
(d) Patient is not receiving Taltz in combination with another targeted
immunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab),
Cosentyx (secukinumab), Simponi (golimumab), Orencia (abatacept),
adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib)]
-AND-
© 2025 UnitedHealthcare Services Inc.
6
(e) Prescribed by or in consultation with a rheumatologist
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b For Connecticut, Kentucky and Mississippi business only a 30-day trial will be required.
c For a list of preferred products please reference drug coverage tools.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Exclusion: Taltz is excluded from coverage for the majority of our benefits
• Supply limits may be in place.
4. References:
1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2022.
2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the
treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-50.
3. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of
psoriasis and psoriatic arthritis. Psoriatic arthritis: Overview and guidelines of care for
treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58(5):851-64.
4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of
psoriasis with topical therapies. J Am Acad Dermatol 2009;60(4):643-59.
5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Guidelines of care for the treatment of psoriasis with phototherapy and
photochemotherapy. J Am Acad Dermatol 2010;62(1):114-35.
6. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis
and psoriatic arthritis. Guidelines of care for the management and treatment of psoriasis with
traditional systemic agents. J Am Acad Dermatol 2009;61(3):451-85.
7. Nast A, et al; European S3-Guidelines on the systemic treatment of psoriasis vulgaris –
update 2015 – short version – EFF in cooperation with EADV and IPC, J Eur Acad Derm
Venereol 2015;29:2277-94.
8. Menter A, Korman NJ, Elmets CA,Feldman SR, Gelfand JM, Gordon KB, Guidelines of care
for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the
treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based
conclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-74.
9. Gossec L, et al; European League Against Rheumatism (EULAR) recommendations for
the management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann
Rheum Dis 2016;75:499-510.
© 2025 UnitedHealthcare Services Inc.
7
10. Ward MM, Deodhar A, Dubreuil M, et al. 2019 update of the american college of
rheumatology/spondylitis association of america/spondyloarthritis research and treatment
network recommendations for the treatment of ankylosing spondylitis and nonradiographic
axial spondyloarthritis. Arthritis Rheumatol. 2019; Aug 22. doi: 10.1002/art.41042.
11. Menter A, Strober BE, Kaplan DH et al. Joint AAD-NPF guidelines of care for the
management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019:80:1029-
72.
Program Prior Authorization/Medical Necessity-Taltz (ixekizumab)
Change Control
Date Change
8/2016 New Program.
11/2016 Administrative change. Added California coverage information.
5/2017 Updated disease severity criteria to include facial, genital area psoriasis,
decreased to 5% of body surface area. Added criteria for patients
already receiving Taltz. Updated references. Updated State Mandate
Reference
2/2018 Updated background and added criteria for new indication of psoriatic
arthritis. Updated criteria adding Tremfya as additional preferred
option for plaque psoriasis. Updated formatting without changes to
clinical intent. Updated references.
2/2019 Annual review. Updated background and criteria adding Cimzia to list
of preferred products for the treatment of plaque psoriasis. Updated
reference.
9/2019 Updated background and criteria to include new indication for active
ankylosing spondylitis. Updated criteria for psoriasis and psoriatic
arthritis. Added coverage exclusion statement. Updated references.
5/2020 Updated program to include new indication in pediatric patients with
plaque psoriasis. Updated criteria for psoriatic arthritis and ankylosing
spondylitis pertaining to nonbiologic therapies. Updated references.
7/2020 Updated background and criteria to include new indication for non-
radiographic axial spondyloarthritis. Clarified documentation
requirements. Updated references.
11/2020 Added Tremfya as a step therapy medication for psoriatic arthritis.
Revised formatting for psoriasis section to match other sections.
Modified psoriasis step requirement due to expanded indication for
Stelara.
6/2021 Added coverage criteria for patients previously treated with a biologic
DMARD.
12/2021 Updated the following with no change to clinical intent: updated
conventional DMARD bypass language for psoriatic arthritis and
psoriasis, removed “biologic” from required preferred product criteria
language, updated age requirement language and updated CT/KY
footnote.
3/2022 Added Skyrizi as a preferred drug for active psoriatic arthritis.
6/2022 Added Rinvoq and Xeljanz to step therapy medication for ankylosing
spondylitis and Rinvoq to psoriatic arthritis. Added Rinvoq and/or
Xeljanz to examples where appropriate. Added Mississippi to state
mandate footnote.
© 2025 UnitedHealthcare Services Inc.
8
11/2022 Added Enbrel as a preferred product step option for PsO, PsA, and AS.
Added Enbrel as an example where appropriate. Added Rinvoq as a
step option for non-radiographic axial spondyloarthritis. Updated
reference. Added targeted synthetic to DMARD bypass for non-
radiographic axial spondyloarthritis.
1/2023 Updated step therapy requirements to Humira or Amjevita. Updated
listed examples from Humira to adalimumab.
4/2023 Updated step therapy requirement from Humira or Amjevita to one of
the preferred adalimumab products and added the footnote “For a list of
preferred adalimumab products please reference drug coverage tools.”
7/2023 Updated not receiving in combination language to targeted
immunomodulator and updated examples.
10/2024 Updated step requirement noting Adalimumab-adaz (unbranded
Hyrimoz), Amjevita for Nuvaila, and Humira as preferred adalimumab
products with no change to clinical intent. Removed preferred
adalimumab footnote. Added Sotyktu as step therapy agent for PsO.
Moved Cosentyx to preferred step agent. Updated state mandate
footnote.
4/2025 Removed examples for adalimumab in step therapy. Changed Stelara
step therapy to “One of the preferred ustekinumab productsc”. Changed
Stelara example to Ustekinumab. Added the footnote “For a list of
preferred products please reference drug coverage tools.”
© 2025 UnitedHealthcare Services Inc.
9